Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
710 (USA) · Dr. Silva
consented 2012-12-15
AEs
4
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild APPLICATION SITE IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-02-13 (study day 61.0); relationship: POSSIBLE
moderate
assessed
Moderate BLISTER — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-02-10 (study day 58.0); relationship: POSSIBLE
moderate
assessed
Moderate ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-02-10 (study day 58.0); relationship: POSSIBLE
moderate
assessed
Moderate PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-01-31 (study day 48.0); relationship: POSSIBLE
Data queries
No data queries.